Get access

Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet

Authors

  • Jiyun Ahn,

    1. Food Function Research Center, Korea Food Research Institute, Seoungnam, Korea
    2. Division of Food Biotechnology, University of Science and Technology, Daejeon, Korea
    Search for more papers by this author
  • Hyunjung Lee,

    1. Food Function Research Center, Korea Food Research Institute, Seoungnam, Korea
    Search for more papers by this author
  • Chang Hwa Jung,

    1. Food Function Research Center, Korea Food Research Institute, Seoungnam, Korea
    2. Division of Food Biotechnology, University of Science and Technology, Daejeon, Korea
    Search for more papers by this author
  • Taeyoul Ha

    Corresponding author
    1. Division of Food Biotechnology, University of Science and Technology, Daejeon, Korea
    • Food Function Research Center, Korea Food Research Institute, Seoungnam, Korea
    Search for more papers by this author

Correspondence: Dr. Taeyoul Ha, Food Function Research Center, Korea Food Research Institute, 516, Baekhyung, Bundang, Seoungnam, Gyeonggi 463-746, Korea

E-mail: tyhap@kfri.re.kr

Fax: +82-31-780-9225

Abstract

Scope

Nonalcoholic fatty liver disease (NAFLD) is a chronic disorder characterized by hepatic fat accumulation and abnormal lipid metabolism. Here, we investigated the protective effect of lycopene on high-fat diet-induced hepatic steatosis and fatty acid-induced intracellular lipid accumulation by miRNA regulation.

Methods and results

C57BL/6J mice were fed high-fat diet with or without 0.05% lycopene for 8 weeks. Hepa 1–6 cells were treated with stearic acid (SA) after 24 h pretreatment with lycopene. Treatment of lycopene improved hepatic steatosis in high-fat-fed mice and reduced intracellular lipid accumulation induced by SA in Hepa 1–6 cells. We demonstrated that miR-21 expression was decreased in livers from high-fat diet-fed mice and Hepa 1–6 cells treated with SA. Lycopene normalized the downregulation of miR-21, which led to the downregulation of fatty acid-binding protein 7 (FABP7), a direct target of miR-21, at both the transcriptional and translational levels. This specific negative regulation of miR-21 was achieved by targeting the FABP7 3′UTR. Upregulation of miR-21 markedly blocked SA-induced intracellular lipid accumulation by blocking FABP7 expression. Moreover, silencing of FABP7 reduced SA-evoked lipid accumulation in Hepa 1–6 cells.

Conclusion

The results suggest that lycopene may be a useful functional compound for treating NAFLD by regulating hepatic lipid metabolism.

Ancillary